🔴 Cerenome is trading 5% down in pre-market with no fresh catalyst identified

Cerenome is trading at $0.85, down 5.22%, with no fresh overnight company catalyst identified.

• On November 4, Cerenome’s Aetna agreement expanded coverage by about 26 million members, bringing its contracted footprint to approximately 190 million lives; shares fell despite the news.
• The announcement does not explain the current decline. Healthcare is higher and broader pre-market markets are mixed; neither clearly accounts for the move.
• Shares had already fallen sharply in the prior two sessions.